*Dr. Mohammed Ashfaq Hussain, Tahmeena Tabassum, Fatima Farooq, Mohammed Abdullah Ali, Ayesha Fatima Sohail, Dr. C. Raghu and Anupama Koneru


Background: In patients with HFrEF, treated with sacubitril/valsartan, the treatment benefits were seen which reflects the LV reverse remodelling and predicts the prognosis. Objective: The purpose of this study was to analyse the pharmacotherapeutic evaluation of sacubitril/valsartan in HF patients. Methodology: This prospective observational study was performed in the Department of Cardiology, in Aster Prime Hospital, Ameerpet, Hyderabad. The echo parameters such as ejection fraction, mitral regurgitation, diastolic dysfunction, and cardiac enzyme, NT- pro BNP, adverse events, NYHA Classification and quality of life using KCCQ-12 score were obtained at baseline and follow-up was done after 3 months. The data recorded were statistically analysed using SPSS version 2020, Chi-square test, dependent-t test and Pearson’s correlation. Results: Analysis was done in a sample size of 88 patients. Statistical improvement was noticed in ejection fraction, mitral regurgitation and diastolic dysfunction, with a P-value of (< 0.0001), (0.0080) and (0.0008) respectively, and NT- pro BNP levels was reduced with a P-value of (<0.0001). There is a direct proportional relationship in improvement of KCCQ score with NYHA classification. In this study, it was analysed that 19% of patients improved to NYHA Class 1 after treatment. The impact of sacubitril/ valsartan on KCCQ score domains, the total symptom frequency score, clinical summary score, and overall score show statistical improvement over 3 months, with a P-value of (< 0.0001). Conclusion: This study concludes, that after initiation of sacubitril/valsartan, significant changes were observed in echo parameters, and KCCQ-12 score with respect to NYHA class, which minimizes the chances of death and rehospitalization due to cardiovascular complications, with minimal adverse effects thereby indicating improvement in the quality of life and overall health status of the patients.

Keywords: Sacubitril/ valsartan, ejection fraction, NT- pro BNP, Heart failure, NYHA Classification, and KCCQ- 12 score.

[Full Text Article]   [Download Certificate]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    MARCH 2024 Issue has been successfully launched on 1 MARCH 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction